Category: Regions

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM
September 30, 2024 Off

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM

By Dino Mustafić

Formycon AG and its commercialization partner Fresenius Kabi jointly said Monday that the U.S. Food and Drug Administration (FDA) has approved FYB202/OtulfiTM1 (ustekinumab-aauz), a biosimilar to Stelara, for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis, the third Formycon biosimilar successfully approved by the FDA.

Breas and ovarian cancer newly linked to thousands of gene variants
September 18, 2024 Off

Breas and ovarian cancer newly linked to thousands of gene variants

By Dino Mustafić

Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known to increase ovarian cancer risk six-fold and risk of aggressive subtypes of breast cancer four-fold. They found over 3,000 harmful genetic changes that could potentially disrupt its function and increase cancer risk. These findings were confirmed by analysing data from large-scale health databases.